ASH Clinical News December 2014 | Page 25
The ClonoSIGHT Process:
™
Reveal deeper MRD
Ultra-sensitive sequencing-based
MRD assessment for lymphoid cancers
Universal, standardized assay
Specimen flexibility
Secure online results portal
Learn more at clonosight.com
Visit us at the
56th ASH
Annual Meeting
Booth #1243